Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

By B. Fisher, J. Costantino, D. Wickerham, R. Cecchini, W. Cronin, A. Robidoux, T. Bevers, M. Kavanah, J. Atkins, R. Margolese and 4 more. Journal of the National Cancer Institute, 2005

1,333 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ba4049672ccacb5319d9922aea38b7efd5572881

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Victor G. Vogel
2. J. Costantino
3. C. Runowicz
4. D. Wickerham
5. W. Cronin
6. R. Cecchini
7. J. Atkins
8. T. Bevers

Citations in the corpus

• Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010, positive): “Cancer Prev Res; 3(6) June 2010 trials of tamoxifen in women at risk for the future development of breast cancer, 5 to 8 years of tamoxifen significantly reduced the incidence of invasive breast cancer, and this benefit persisted for at least 7 to 12 years (6, 15, 16).”